BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37302522)

  • 1. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
    Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
    Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
    Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
    Koganemaru S; Kuboki Y; Koga Y; Kojima T; Yamauchi M; Maeda N; Kagari T; Hirotani K; Yasunaga M; Matsumura Y; Doi T
    Mol Cancer Ther; 2019 Nov; 18(11):2043-2050. PubMed ID: 31395690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
    Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
    Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
    Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
    Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA
    Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.
    Haratani K; Yonesaka K; Takamura S; Maenishi O; Kato R; Takegawa N; Kawakami H; Tanaka K; Hayashi H; Takeda M; Maeda N; Kagari T; Hirotani K; Tsurutani J; Nishio K; Doi K; Miyazawa M; Nakagawa K
    J Clin Invest; 2020 Jan; 130(1):374-388. PubMed ID: 31661465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
    Koyama K; Ishikawa H; Abe M; Shiose Y; Ueno S; Qiu Y; Nakamaru K; Murakami M
    PLoS One; 2022; 17(5):e0267027. PubMed ID: 35503762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.
    Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X
    Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors.
    Kong C; Pu J; Zhao Q; Weng W; Ma L; Qian Y; Hu W; Meng X; Meng T
    Mol Cancer Ther; 2023 Oct; 22(10):1128-1143. PubMed ID: 37352387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
    Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
    Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.